Peptides by condition · Heart, kidneys and lungs

Peptides studied for heart disease

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 17 study pages on heart disease: 12 in people (11 of them meta-analyses or randomized trials), and 5 in animals. They studied 14 compounds, with this many study pages each: Semaglutide 2, Semaglutide (oral) 2, SS-31 2, Exenatide 1, Dulaglutide 1, Liraglutide 1, Orforglipron 1, NAD+ 1, Thymosin Beta-4 1, Ac-SDKP 1, BPC-157 1, Hexarelin 1, PEG-MGF 1 and SLU-PP-332 1.

What the research on heart disease looks like

Heart disease covers narrowed heart arteries, heart attacks, heart failure and irregular rhythms. The peptide studies on it come in two kinds: large trials that followed people with diabetes or excess weight for years and counted heart attacks, strokes and heart deaths, and smaller studies that gave a peptide around a heart attack to see whether it limited the damage.

The large trials count a combined outcome, usually death from heart causes, a nonfatal heart attack or a nonfatal stroke, and report it as a hazard ratio against placebo. The heart attack studies measure the size of the damaged area on a scan.

A trial that only shows a drug is no worse for the heart than placebo answers a safety question, not whether it lowers risk, so read which question a trial was built to answer. Results in rat or mouse hearts are early.

Our study pages on heart disease by design: Trials in people 11, Other in people 1, Animals 5, Cells 0, of 17.Trials in people11Other in people1Animals5Cells0
How many of the 17 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.
A smiling woman with silver hair in a grey training top by a window, holding her phone

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The 17 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Semaglutide

    2 in people

    For heart disease, 2 of our study pages are filed under Semaglutide: 2 randomized trials in people. The largest in people enrolled 17,604 people and was published in 2023. They were published from 2016 to 2023, in N Engl J Med.

    FDA-approved, with a use tied to heart disease on its label: Ozempic (injection) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and kidney decline in those with heart or kidney disease; Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Wegovy (injection) for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and a fatty-liver disease (MASH) with moderate to advanced scarring; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus).

  2. For heart disease, 2 of our study pages are filed under Semaglutide (oral): 2 randomized trials in people. The largest in people enrolled 9,650 people and was published in 2025. They were published from 2019 to 2025, in N Engl J Med.

    FDA-approved, with a use tied to heart disease on its label: Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus).

  3. SS-31

    2 in people

    For heart disease, 2 of our study pages are filed under SS-31: 1 randomized trial and 1 clinical trial in people. Its studies in people do not give their size on our pages. They were published from 2016 to 2019, in Eur Heart J and Eur Heart J Acute Cardiovasc Care.

    FDA-approved for other uses, not for heart disease: Forzinity (injection) for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg (an accelerated approval; it may depend on a confirmatory trial).

  4. Exenatide

    1 in people

    For heart disease, 1 of our study pages is filed under Exenatide: 1 randomized trial in people. It enrolled 14,752 people and was published in 2017, in N Engl J Med.

    FDA-approved for other uses, not for heart disease: Byetta (injection) for blood sugar control, with diet and exercise, in adults with type 2 diabetes.

  5. Dulaglutide

    1 in people

    For heart disease, 1 of our study pages is filed under Dulaglutide: 1 randomized trial in people. It enrolled 9,901 people and was published in 2019, in Lancet.

    FDA-approved, with a use tied to heart disease on its label: Trulicity (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease or several heart risk factors.

  6. Liraglutide

    1 in people

    For heart disease, 1 of our study pages is filed under Liraglutide: 1 randomized trial in people. It enrolled 9,340 people and was published in 2016, in N Engl J Med.

    FDA-approved, with a use tied to heart disease on its label: Victoza (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease. Under Saxenda it is approved for other uses.

  7. Orforglipron

    1 in people

    For heart disease, 1 of our study pages is filed under Orforglipron: 1 randomized trial in people. It enrolled 2,749 people and was published in 2026, in Lancet.

    FDA-approved for other uses, not for heart disease: Foundayo (tablet) for weight loss and keeping it off, in adults with obesity or with excess weight and a weight-related condition.

  8. NAD+

    1 in people

    For heart disease, 1 of our study pages is filed under NAD+: 1 randomized trial in people. It enrolled 180 people and was published in 2026, in Am J Cardiovasc Drugs.

    NAD+ has no FDA-approved drug: Drugs@FDA lists no application for it.

  9. Thymosin Beta-4

    1 in people

    For heart disease, 1 of our study pages is filed under Thymosin Beta-4: 1 randomized trial in people. It enrolled 96 people and was published in 2025, in Cardiovasc Res.

    Thymosin beta-4 has no FDA-approved product: Drugs@FDA lists no application for it.

  10. Ac-SDKP

    1 in animals

    For heart disease, 1 of our study pages is filed under Ac-SDKP: 1 animal study (mice). It was published in 2019, in Can J Physiol Pharmacol.

    Ac-SDKP has no FDA-approved product: Drugs@FDA lists no application for it.

  11. BPC-157

    1 in animals

    For heart disease, 1 of our study pages is filed under BPC-157: 1 animal study (rats). It was published in 2022, in Biomedicines.

    BPC-157 has no FDA-approved product: Drugs@FDA lists no application for it.

  12. Hexarelin

    1 in animals

    For heart disease, 1 of our study pages is filed under Hexarelin: 1 animal study (rats). It was published in 1999, in Endocrinology.

    Hexarelin (examorelin) has no FDA-approved product: Drugs@FDA lists no application for it.

  13. PEG-MGF

    1 in animals

    For heart disease, 1 of our study pages is filed under PEG-MGF: 1 animal study (mice). It was published in 2013, in Mol Cell Biochem.

    PEG-MGF has no FDA-approved product: Drugs@FDA lists no application for it.

  14. SLU-PP-332

    1 in animals

    For heart disease, 1 of our study pages is filed under SLU-PP-332: 1 animal study (mice). It was published in 2024, in Circulation.

    SLU-PP-332 has no FDA-approved product: Drugs@FDA lists no application for it.

Side by side

For the 14 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Semaglutide2017,604Approved, a use tied to it
Semaglutide (oral)209,650Approved, a use tied to it
SS-3120—Approved for other uses
Exenatide1014,752Approved for other uses
Dulaglutide109,901Approved, a use tied to it
Liraglutide109,340Approved, a use tied to it
Orforglipron102,749Approved for other uses
NAD+10180Not approved
Thymosin Beta-41096Not approved
Ac-SDKP01—Not approved
BPC-15701—Not approved
Hexarelin01—Not approved
PEG-MGF01—Not approved
SLU-PP-33201—Not approved

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for heart disease?

Our 17 study pages on heart disease are filed under 14 compounds, with this many each: Semaglutide 2, Semaglutide (oral) 2, SS-31 2, Exenatide 1, Dulaglutide 1, Liraglutide 1, Orforglipron 1, NAD+ 1, Thymosin Beta-4 1, Ac-SDKP 1, BPC-157 1, Hexarelin 1, PEG-MGF 1 and SLU-PP-332 1. Semaglutide, Semaglutide (oral) and SS-31 have the most, 2 each.

Have any been tested in people with heart disease?

Yes: 12 of the 17 were in people, 11 of them meta-analyses or randomized trials (Semaglutide, Semaglutide (oral), SS-31, Exenatide, Dulaglutide, Liraglutide, Orforglipron, NAD+ and Thymosin Beta-4). The largest enrolled 17,604 people: “Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT” (2023).

Is any peptide FDA-approved for heart disease?

Yes, with a use tied to heart disease on their FDA labels: Semaglutide as Ozempic, Rybelsus and Wegovy; Semaglutide (oral) as Rybelsus, Wegovy and Ozempic; Dulaglutide as Trulicity; Liraglutide as Victoza. 10 other compounds here with an FDA record have no use tied to it.

How large were the studies in people on heart disease?

Of the 12 in people, 10 give their size on our pages: 8 had 1,000 people or more, 1 had 100 to 999 and 1 had fewer than 100. The largest, a randomized trial from 2023, enrolled 17,604.

What did the animal and cell studies on heart disease use?

5 animal studies (mice and rats), filed under SLU-PP-332, BPC-157, Ac-SDKP, PEG-MGF and Hexarelin. A result in animals or cells shows what to test next, not what happens in a person.

What is the newest study on heart disease here?

Of our study pages on heart disease, the newest is “Orforglipron: heart events no worse than insulin in ACHIEVE-4”, a randomized trial in people published in 2026.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

Track it in the app

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo